The differences did not reach statistical significance when adalimumab was compared with either etanercept or infliximab.
← all excerpts
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
2
—
—
The sentences
No significant difference was apparent when comparing the rates of shingles with etanercept with the monoclonal antibodies combined.